LEUSTATIN

This brand name is authorized in Australia, Brazil, Spain, Japan, Netherlands, New Zealand, South Africa

Active ingredients

The drug LEUSTATIN contains one active pharmaceutical ingredient (API):

1 Cladribine UNII 47M74X9YT5 - CLADRIBINE

Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death. Read about Cladribine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BB04	Cladribine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 4326Q, 7225G
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 514501902157315
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 61380
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291408A1021
Country: NL	Z-Index G-Standaard	Identifier(s): 13927280
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 41785
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7163
Country: ZA	Health Products Regulatory Authority	Identifier(s): 29/26/0404